98%
921
2 minutes
20
The key biological "drivers" that are responsible for reverse left ventricle (LV) remodeling are not well understood. To gain an understanding of the role of the autophagy-lysosome pathway in reverse LV remodeling, we used a pathophysiologically relevant murine model of reversible heart failure, wherein pressure overload by transaortic constriction superimposed on acute coronary artery (myocardial infarction) ligation leads to a heart failure phenotype that is reversible by hemodynamic unloading. Here we show transaortic constriction + myocardial infarction leads to decreased flux through the autophagy-lysosome pathway with the accumulation of damaged proteins and organelles in cardiac myocytes, whereas hemodynamic unloading is associated with restoration of autophagic flux to normal levels with incomplete removal of damaged proteins and organelles in myocytes and reverse LV remodeling, suggesting that restoration of flux is insufficient to completely restore myocardial proteostasis. Enhancing autophagic flux with adeno-associated virus 9-transcription factor EB resulted in more favorable reverse LV remodeling in mice that had undergone hemodynamic unloading, whereas overexpressing transcription factor EB in mice that have not undergone hemodynamic unloading leads to increased mortality, suggesting that the therapeutic outcomes of enhancing autophagic flux will depend on the conditions in which flux is being studied.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831862 | PMC |
http://dx.doi.org/10.1016/j.jacbts.2022.06.003 | DOI Listing |
ESC Heart Fail
September 2025
Department of Cardiac-, Thoracic-, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Aims: Non-pharmacological therapies for acute decompensated heart failure (HF) and cardiogenic shock have evolved considerably in recent decades. Short-term mechanical circulatory support (MCS) devices can be used as circulatory backup. While nearly all available devices use continuous flow, evidence indicates that pulsatile flow can be more effective.
View Article and Find Full Text PDFJ Cardiovasc Dev Dis
July 2025
Division of Cardiology, Annunziata Hospital, 87100 Cosenza, Italy.
Cardiac devices have transformed the management of heart failure, ventricular arrhythmias, ischemic cardiomyopathy, and valvular heart disease. Technologies such as cardiac resynchronization therapy (CRT), conduction system pacing, left ventricular assist devices (LVADs), and implantable cardioverter-defibrillators have contributed to abated global cardiovascular risk through action onto pathophysiological processes such as mechanical unloading, electrical resynchronization, or hemodynamic optimization, respectively. While their clinical benefits are well established, their long-term molecular and structural effects on the myocardium remain under investigation.
View Article and Find Full Text PDFJACC Case Rep
August 2025
Department of Cardiology, University Heart Center Graz, Graz, Austria. Electronic address:
Background: In hemodynamically unstable patients on venoarterial extracorporeal membrane oxygenation (VA-ECMO), left ventricular unloading may be essential but technically challenging, especially after aortic valve replacement.
Case Summary: We report a case of a 64-year-old male patient with postcardiotomy cardiogenic shock after combined coronary and aortic valve surgery. VA-ECMO alone was insufficient, prompting the use of a microaxial flow pump via axillary access.
Cureus
July 2025
Division of Cardiovascular Surgery, Department of Surgery, Kurume University, Kurume, JPN.
Objective: ST-segment elevation myocardial infarction (STEMI) often requires urgent revascularization, with percutaneous coronary intervention (PCI) as the primary strategy. However, coronary artery bypass grafting (CABG) remains essential in cases where PCI is either unfeasible or fails. Emergency CABG for STEMI is associated with high operative risk and poor outcomes, especially in hemodynamically unstable patients.
View Article and Find Full Text PDFJ Cardiothorac Surg
August 2025
Department of Cardiac Surgery, TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences ï¿¿ Peking Union Medical College, Tianjin, 300457, China.
In recent years, the use of Left Ventricular Assist Devices (LVAD) in the treatment of heart failure has been increasingly widespread. Not only do they provide circulatory support for patients, but the reverse biological changes in myocardial tissue induced by LVAD have led to the recovery of heart function in some patients, allowing for the removal of the device-which termed bridge to recovery (BTR). Despite promising prospective studies reporting LVAD explantation rates exceeding 48-60% in BTR-focused cohorts, real-world registries (e.
View Article and Find Full Text PDF